Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

PubMed  Google Scholar 

Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guidelines for the management of non-ST elevation acute coronary syndromes (2024). Article in Chinese. Chin J Cardiol. 2024,52:(06): 615-646.

Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology Interventional Cardiology Working Group of Chinese Society of Cardiology Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, et al. Dual antiplatelet therapy in patients with coronary artery disease. Chin J Cardiol. 2021,49:(05): 432-454.

Dai C, Chen Z, Fu J, Qian J, Ge J. Cilostazol for Chinese patients with aspirin intolerance after coronary drug-eluting stent implantation. Thromb Haemost. 2020;120:857–65.

PubMed  Google Scholar 

Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol. 2013;110:92–5.

CAS  PubMed  Google Scholar 

Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol. 2011;8(7):385–94.

CAS  PubMed  Google Scholar 

Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(27):2362–76.

CAS  PubMed  PubMed Central  Google Scholar 

Sarajlic P, Simonsson M, Jernberg T, Bäck M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2022;8(5):483–91.

PubMed  Google Scholar 

Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC Guidelines on dual antiplatelet therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915–31.

PubMed  Google Scholar 

Carlin S, de Vries TAC, Budaj A, Eikelboom J. Dual pathway inhibition for atherosclerotic cardiovascular disease: recent advances. Kardiol Pol. 2022;80(12):1200–10.

PubMed  Google Scholar 

Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.

CAS  PubMed  Google Scholar 

Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.

CAS  PubMed  Google Scholar 

Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017;135:323–33.

CAS  PubMed  PubMed Central  Google Scholar 

Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.

CAS  PubMed  Google Scholar 

Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015;20:554–62.

CAS  PubMed  PubMed Central  Google Scholar 

Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.

CAS  PubMed  Google Scholar 

Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68:1389–401.

CAS  PubMed  Google Scholar 

Ogawa S, Ikeda T, Kitazono T, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis. 2014;23:2520–6.

PubMed  Google Scholar 

Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 2017;33:1955–63.

CAS  PubMed  Google Scholar 

Lee HF, Chan YH, Tu HT, et al. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. Int J Cardiol. 2018;261:78–83.

PubMed  Google Scholar 

Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol. 2018;72(5):477–85.

CAS  PubMed  Google Scholar 

Zhou T, Gong Y, Li J, Wang Y, Wang X. Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial. Trials. 2023;24(1):209.

CAS  PubMed  PubMed Central  Google Scholar 

Study Group of Gastrointestinal Motility, Study Group of Functional Gastrointestinal Disorders, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on the management of functional dyspepsia (2015, Shanghai). Chinese Journal of Digestion. 2016,36(4): 217-229.

Fang H, Fang X, Guo J. Research on the implementation of the randomized process based on SPSS in data analysis course. Journal of Langfang Normal University (Natural Science Edition). 2016;16(04):20-23+27.

Zheng YY, Wu TT, Guo QQ, et al. Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease. Atherosclerosis. 2021;328:1–10.

CAS  PubMed  Google Scholar 

Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29-38.

Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.

CAS  PubMed  Google Scholar 

Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–85.

PubMed  Google Scholar 

Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.

CAS  PubMed  Google Scholar 

Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183–200.

CAS  PubMed  Google Scholar 

Nguyen E, White CM, Patel MR, et al. Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin. 2016;32(7):1277–9.

CAS  PubMed  Google Scholar 

Khan SU, Khan MZ, Asad ZUA, et al. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):913–20.

CAS  PubMed  PubMed Central  Google Scholar 

Mu G, Zhang H, Liu Z, et al. Standard- vs low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(2):181–90.

CAS  PubMed  Google Scholar 

Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121(4):422–32.

PubMed  Google Scholar 

Numasawa Y, Kohsaka S, Ueda I, et al. Incidence and predictors of bleeding complications after percutaneous coronary intervention. J Cardiol. 2017;69(1):272–9.

PubMed  Google Scholar 

Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the bright randomized clinical trial. JAMA. 2015;313:1336–46.

CAS  PubMed  Google Scholar 

Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Article in Chinese. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766-783.

Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Antithrombotic management of atrial fibrillation patients presenting with coronary artery disease: a consensus document of the Chinese society of cardiology. Cardiol Discov. 2021;1(1)15–28.

Zhai Y, Ye X, Hu F, et al. Updated insights on cardiac and vascular risks of proton pump inhibitors: a real-world pharmacovigilance study. Front Cardiovasc Med. 2022;9: 767987.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou M, Zhang J, Liu J, et al. Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy. Mayo Clin Proc. 2022;97(4):682–92.

CAS  PubMed  Google Scholar 

Dai WB, Ren JY, Hu ST, et al. The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention. Platelets. 2024;35(1):2364748.

PubMed  Google Scholar 

Hernandez-Juarez J, Espejo-Godinez HG, Mancilla-Padilla R, et al. Effects of rivaroxaban on platelet aggregation. J Cardiovasc Pharmacol. 2020;75(2):180–4.

CAS  PubMed  Google Scholar 

Mazzone PM, Capodanno D. Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease. J Thromb Thrombolysis. 2023;56(1):91–102.